References
  1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. (2003) Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004
  2. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917-27
  3. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 362:2251-2259
  4. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 362:2260-2270
  5. Hochhaus A, et al. (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044-54
  6. Cortes JE, et al. (2016) Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333-40
  7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
  8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
  9. Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, et al. (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 22:2073-2079
  10. Kitiyakara C, Atichartakarn V. (2002) Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 17:685-687
  11. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. (2010) Renal failure associated with tyrosine kinase inhibitors—case report and review of the literature. Leuk Res 34:123-127
  12. Pou M, Saval N, Vera M, Saurina A, Sole M, Cervantes F, et al. (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44:1239-1241
  13. Al Aly Z, Philoctete Ashley JM, Gellens ME, Gonzalez EA. (2005) Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? Am J Kidney Dis 45:762-768
  14. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. (2005) Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39:2136-2138
  15. Francois H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P. (2008) Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 51:298-301
  16. Shibuya Y, Matsuo K, Kosugi T, Gomi T. (2004) Pharmacokinetics and side effects of imatinib mesilate (Glivec®) in a hemodialysis patient with chronic myeloid leukemia. Journal of Japanese Society for Dialysis Therapy 37:239-42
  17. Nakahara R, Sato Y, Itoh H. (2016) High-performance liquid chromatographic ultraviolet detection of nilotinib in human plasma from patients with chronic myeloid leukemia, and comparison with liquid chromatography-tandem mass spectrometry. J Clin Lab Anal. 30,1028-1030
  18. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109, 3496-3499
  19. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. (2012) Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica 97(5):731-738
  20. Baccarani M, et al. (2013) European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood 122:872-884
  21. Nakahara R, Sumimoto T, Ogata M, Sato Y, Itoh H. (2019) Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report. Clin Case Rep., 7:1419-1421
  22. Miura M. (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 38(5):645-654
  23. Peng B, Lloyd P, Schran H. (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-94
  24. Ladda MA, Goralski KB. (2016) The Effects of CKD on cytochorome P450‒medeiated drug metabolism. Adv Chronic Kidney Dis 23:67-75
  25. Uchida N, Kurata N, Shimada K, et al. (1995) Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (eCRF) rats by partial nephrectomy. Jpn J Pharmacol 68:431-9